Phase I/II Clinical Trials for Theradaptive OsteoAdapt SP
Theradaptive gained FDA approval for their IDE submission to enroll patients into OASIS, a global Phase I/II Feasibility study in spine fusion. Feb 01, 2024
We've found 7 results
Theradaptive Awarded DOD Clinical Trial Award
This award will help Theradaptive scale up the production of its OsteoAdapt regenerative therapeutic product for spine and trauma repair. Sep 26, 2023
Theradaptive Closes $26 Million Investment Round
The company's proprietary protein-engineering platform produces targeted therapeutics that can coat implants and devices to achieve hyper-local delivery over long time periods. Jun 15, 2023
Theradaptive Awarded Contract for OsteoAdapt Regenerative Therapeutic
Funds will support work to meet regulatory requirements for the OsteoAdapt product in preparation for clinical studies. Mar 01, 2023
Theradaptive Secures Third FDA Breakthrough Designation
FDA granted Breakthrough Medical Device designation for the use of OsteoAdapt SP in Anterior Lumbar Interbody Fusion. Jun 22, 2022
Theradaptive Granted Breakthrough Device Designation
This is the second Breakthrough Designation for Theradaptive in spinal fusion, granted for the OsteoAdapt SP implant. Feb 16, 2022
FDA Grants Breakthrough Device Status to Theradaptive
The Osteo-Adapt SP Spinal Fusion implant is indicated for use in transforaminal lumbar interbody spinal fusion. Nov 22, 2021
